$HBIO Q2 '26 Earnings Results & Recap
• Reported GAAP EPS of -$0.64 down -28.00% YoY
• Reported revenue of $22.73M up 11.13% YoY
• Harvard Bioscience expects full-year 2026 revenue growth between 3% and 5%, with adjusted gross margin between 57% and 59% and adjusted EBITDA growth between 6% and 10% for the year.